Full-Life Technologies

Fulgent Pharma LLC is a clinical-stage pharmaceutical company that develops innovative cancer therapeutics using a patented nanoencapsulation technology. The company focuses on improving existing chemotherapy drugs and creating new drug candidates to treat various cancers while reducing toxicity and enhancing drug delivery and safety.

Ratio TherapeuticsBiotechUnited States

67% match

Ratio Therapeutics is a clinical-stage pharmaceutical company headquartered in Boston, Massachusetts. The company employs a suite of innovative technologies for the discovery and early clinical development of targeted radiopharmaceuticals.

Flashpoint TherapeuticsBiotechnologyUnited States

64% match

Flashpoint Therapeutics is a clinical-stage biotechnology research company headquartered in Evanston, Illinois, developing a new class of precision-engineered structural nanomedicines through its proprietary platform.

PhoreMost Ltd is a Cambridge, United Kingdom-based biotechnology and drug discovery company dedicated to turning scientific breakthroughs into life-changing cancer therapies.

Pharos iBio Co., Ltd. is a South Korean biotechnology company that uses artificial intelligence and big-data approaches for drug discovery and development. Its pipeline includes oncology candidates such as PHI-101, a FLT3 inhibitor being developed for acute myeloid leukemia and other cancers, serving patients with difficult-to-treat diseases and pharmaceutical development partners.

Nanjing Leads Biolabs Co., Ltd. is a biotechnology firm currently in the clinical development phase, dedicated to the global discovery, progression, and eventual market launch of innovative antibody-based medications. The company's therapeutic endeavors concentrate on various critical illnesses, including cancerous growths, autoimmune disorders, and other serious medical conditions. A prominent product in its development pipeline is LBL-024, a bispecific antibody engineered to target PD-L1 and 4-1BB, specifically for the treatment of extra-pulmonary neuroendocrine carcinoma. Other significant compounds under development include LBL-034, LBL-033, and LBL-007. Nanjing Leads Biolabs also leverages its proprietary LeadsBody platform, which focuses on CD3 T-cell engagers that have demonstrated promising anti-tumor effects and safety in preliminary studies, as well as the X-body platform, which specializes in 4-1BB/PD-L1 bispecific antibodies. Beyond these, the company is actively researching antibody treatments for oncological, autoimmune, and infectious diseases, and is also engaged in establishing tumor immunoassays. Established in 2012, its primary operations are based in Nanjing, China.